Voquezna denied due to quantity / dose limits by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for voquezna are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Applied Quantity Limits to Voquezna

UnitedHealthcare's quantity-limit (QL) edits cap how much of a drug can be dispensed per fill or per time period. For Voquezna (vonoprazan), UHC's QL is typically tied to the dosing parameters described in the FDA-approved prescribing label. A QL denial means the prescription as written exceeded UHC's allowed supply — either more units per fill, a higher frequency than permitted, or a day supply that surpasses the limit.

## Why Quantity-Limit Denials Are Appealable

If your physician has a documented clinical reason why the standard quantity is medically insufficient — for example, a documented inadequate response at the plan-permitted quantity, or a condition severity that the FDA label supports treating differently — you can appeal:

• Internal appeal: Your prescriber submits a medical-necessity letter explaining why the quantity prescribed is necessary and consistent with the FDA-approved labeling.
• ACA §2719 external review: Available after an internal denial. An independent reviewer will assess whether UHC's quantity limit is consistent with the FDA label and accepted clinical practice. File within approximately four months of the internal denial.
• ERISA §503 (employer plans): Entitles you to the complete clinical rationale and all criteria UHC used, so your appeal can respond to each basis for the limit.
• Expedited review: Available if the standard timeline would seriously endanger your health.

## Key Fact to Establish

Quantity-limit appeals hinge on the FDA label. Obtain the current FDA-approved prescribing information for Voquezna (available at DailyMed). Your appeal should show that the prescribed quantity is within — or is clinically justified relative to — what the label permits. If UHC's limit is more restrictive than the label, that is a strong appellate argument.

## Documentation to Gather

• FDA prescribing label: Download from DailyMed. Note what the label says about dosing frequency and duration for your specific indication.
• UHC's quantity-limit policy: Request the written policy that sets the cap. Compare it to the label.
• Prescriber letter: The physician should state the diagnosis, the clinical reason the prescribed quantity is necessary, reference to the label's dosing guidance, and why the plan-permitted quantity is insufficient for this patient.
• Chart documentation of inadequate response: If you previously tried the plan-permitted quantity and it was inadequate, document that outcome with dates.
• Diagnosis and severity records: Objective evidence (e.g., endoscopy, symptom scoring) that supports the need for the prescribed amount.

## Criteria-Mapping Approach

| UHC quantity-limit basis | Your response | |---|---| | Exceeds plan-permitted units per fill | FDA label showing quantity is within labeled range; prescriber letter | | Exceeds plan-permitted day supply | Clinical documentation of why extended supply is needed | | Frequency exceeds policy | Prescriber letter citing label and clinical severity |

## Next Step

Your prescriber's office can often request a quantity-limit exception at the PA stage before a formal denial. If denial has already been issued, file the internal appeal with the documentation above. Keep your external-review deadline visible — it is the most powerful tool if the internal appeal fails.